Aragen’s formulation manufacturing facility to begin operations in 2023
.png)
Aragen is set to open their new manufacturing facility at their Mallapur campus in Hyderabad, India in January 2023, enhancing the company’s ability to provide scaled manufacturing solutions and clinical supplies to their customers.
Contract research, development, and manufacturing organisation Aragen (Hyderabad, India) have announced the start of operations at its new formulation manufacturing facility in the Mallapur campus, set to begin in January 2023. The new facility aims to strengthen the company’s capacity in delivering clinical supplies through integrated drug substance and product development and manufacturing.
As a research, development, and manufacturing solutions partner, Aragen aims to offer a range of solutions throughout the drug development process for small and large molecule programs. With eight facilities across the globe, Aragen aims to scale and service large pharmaceutical, biotech, agrochemical, and animal health industries. The new facility will offer manufacturing suites purposely built to support wet granulation, roller compaction, and fluid bed coating, amongst other cGMP manufacturing needs.
A wide range of dosage forms will be covered, including oral solids, liquids, topicals, and films, as well as manufacturing technologies to achieve granulation, film coating, spray drying, and tableting. The new facility will enhance Aragen’s New Chemical Entity (NCE) early-stage development capabilities, providing their customers the ability to discover and develop drugs with greater flexibility in multiple dosage forms. Flexible batch sizes can range from 1000–100,000 units with improved process technologies.
Manni Kantipudi, CEO at Aragen Life Sciences, commented on the development: “Aragen is investing in expanding capacities, extending capabilities, and widening its geographic footprint to meet the needs of the global biopharma industry. We understand that our customers rely on our expertise, track record, and solution offerings. With this facility, we will consolidate our drug product development solution offerings and strengthen our position as a one-stop shop for all their needs – transforming ideas into solutions for better health.”
Chief Commercial Officer Ramesh Subramanian added: “The formulation manufacturing facility in Hyderabad is a significant development for us. The new capacity will allow us to address the increasing interest from our customers for integrated development solutions. It also fits in well with our stated vision of becoming the ‘R&D partner of choice’ for our customers. With this drug product facility and our recent acquisition of Intox to provide safety assessment services, we can now assist our partners from HIT through Clinical Proof of Concept-Phase IIB, accelerating their journey towards impacting patients.”
Related News
-
.png)
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
.png)
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News Women in Pharma: Empowering yourself and other women in pharma
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.
-
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News Doctors Without Borders demands transparency from GSK on licensing agreements for preventative HIV treatment
GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker. -
News Sai Life Sciences opens new HPAPI manufacturing facility in Bidar, India
A new HPAPI development and manufacturing block is now open at Sai Life Sciences’ Bidar Manufacturing Campus, expanding the CRDMO’s capabilities in small molecule discovery and commercialisation. -
.png)
News CPHI Pharma Award Winners 2022: CEO of the Year – Aragen Life Sciences
In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, in each of the different categories, from digital innovation to CEO of the year.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance